Asian Currencies Steady as Markets Await U.S. Inflation Data 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
